Paul Lorigan

Considerations in Developing and Delivering a Nonpharmacological Intervention for Symptom Management in Lung Cancer: The Views of Patients and Informal Caregivers

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse eve...

Pembrolizumab versus Ipilimumab in Advanced Melanoma

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La ...

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF...